Prognostic Value of Inflammatory Markers in Nasopharyngeal Carcinoma Patients in the Intensity-Modulated Radiotherapy Era

被引:17
|
作者
Li, Qian [1 ]
Yu, Lushi [1 ]
Yang, Pengcheng [1 ]
Hu, Qinyong [1 ]
机构
[1] Wuhan Univ, Canc Ctr, Renmin Hosp, 238 Jie Fang Rd, Wuhan 430060, Hubei, Peoples R China
来源
基金
中国国家自然科学基金;
关键词
nasopharyngeal carcinoma; neutrophil-to-lymphocyte ratio; platelet-to-lymphocyte ratio; systemic immune inflammation index; systemic inflammatory response index; prognosis; RESPONSE INDEX SIRI; HEMATOLOGICAL BIOMARKERS; CANCER; SURVIVAL; OUTCOMES; PATTERNS; NOMOGRAM; RATIO;
D O I
10.2147/CMAR.S311094
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Inflammatory markers have been widely used in various cancers, but rarely in nasopharyngeal carcinoma (NPC). Here, we evaluated the prognostic value of pretreatment neutrophil-to-lymphocyte ratio (NLR), platelet-lymphocyte-ratio (PLR), systemic immune index (SII), and systemic inflammation response index (SIRI) on NPC in the intensitymodulated radiotherapy (IMRT) era. Methods: We retrospectively analyzed data from NPC patients from the Renmin Hospital of Wuhan University, between January 2012 and July 2020. We used Chi-square test or Fisher's exact test to compare the baseline characteristics, then applied Kaplan-Meier (K-M) survival analysis to compare the overall survival (OS) and progression-free survival (PFS) rates. Multivariate Cox proportional risk models were applied to identify independent prognostic factors. Results: We enrolled a total of 342 NPC patients and found optimal cut-off values of 2.65, 184.91, 804.08, and 1.34 for NLR, PLR, SII, and SIRI, respectively. K-M survival analysis revealed that high NLR, PLR, SII, and SIRI were significantly associated with worse OS and PFS relative to those in the low groups. Results from univariate Cox analysis showed that clinical, T, and M stages, as well as NLR, PLR, SII, and SIRI were associated with OS, whereas age, alongside the aforementioned parameters, was associated with PFS. Moreover, multivariate Cox analysis showed that age >49 years (HR=2.48, 95% CI=1.21-5.05, P=0.013) and M1 stage (HR=3.84, 95% CI=1.52-9.73, P=0.013) were independent prognostic factors for OS, whereas SIRI >1.34 (HR=1.91, 95% CI=1.05-3.47, P=0.034) and M1 stage (HR=2.91, 95% CI=1.44-5.86, P=0.003) were independent prognostic factors for PFS. Conclusion: Overall, our findings indicated that high NLR, PLR, SII, and SIRI were significantly associated with poor OS and PFS in NPC patients. High SIRI may be an independent risk factor for PFS of NPC patients in the IMRT era. Keywords: nasopharyngeal carcinoma, neutrophil-to-lymphocyte ratio, platelet-tolymphocyte ratio, systemic immune inflammation index, systemic inflammatory response
引用
收藏
页码:6799 / 6810
页数:12
相关论文
共 50 条
  • [21] Prognostic values of hematological biomarkers in nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy
    Lulu Ye
    Ronald Wihal Oei
    Fangfang Kong
    Tingting Xu
    Chunying Shen
    Xiaoshen Wang
    Xiayun He
    Lin Kong
    Chaosu Hu
    Hongmei Ying
    [J]. European Archives of Oto-Rhino-Laryngology, 2018, 275 : 1309 - 1317
  • [22] Reirradiation of nasopharyngeal carcinoma with intensity-modulated radiotherapy
    Chua, DTT
    Sham, JST
    Leung, LHT
    Au, GKH
    [J]. RADIOTHERAPY AND ONCOLOGY, 2005, 77 (03) : 290 - 294
  • [23] Outcomes of patients with nasopharyngeal carcinoma treated with intensity-modulated radiotherapy
    Yeh, Shyh-An
    Hwang, Tzer-Zen
    Wang, Chih-Chun
    Yang, Chuen-Chien
    Lien, Ching-Feng
    Wang, Chien-Chung
    Hsu, Tun-Yen
    Hsu, Ruey-Feng
    Shih, Yu-Chen
    Huang, Yaw-Chang
    Hsieh, Meng-Che
    Gau, Jhy-Shyan
    Chang, Liyun
    Lee, Tsair-Fwu
    [J]. JOURNAL OF RADIATION RESEARCH, 2021, 62 (03) : 438 - 447
  • [24] Outcomes of patients with nasopharyngeal carcinoma treated with intensity-modulated radiotherapy
    Department of Radiation Oncology, E-DA Hospital, Kaohsiung City, Taiwan
    不详
    不详
    不详
    不详
    不详
    不详
    [J]. J. Rad. Res., 1600, 3 (438-447):
  • [25] The development and external validation of simplified T category classification for nasopharyngeal carcinoma to improve the prognostic value in the intensity-modulated radiotherapy era
    Tang, Ling-Long
    Liang, Shao-Bo
    Huang, Cheng-Long
    Zhang, Fan
    Xu, Cheng
    Mao, Yan-Ping
    Tian, Li
    Lin, Ai-Hua
    Li, Li
    Sun, Ying
    Ma, Jun
    [J]. CANCER MEDICINE, 2019, 8 (05): : 2213 - 2222
  • [26] Clinical outcome and prognostic analysis of young adults nasopharyngeal carcinoma patients of a nonendemic area in intensity-modulated radiotherapy era
    Huang, Yecai
    Zhang, Jingqiu
    He, Qiao
    Ian, Mei
    Feng, Mei
    Zhou, Jie
    Xu, Peng
    Li, Lu
    Yin, Jun
    Lang, Jinyi
    [J]. FUTURE ONCOLOGY, 2019, 15 (04) : 381 - 389
  • [27] Prognostic value of Diabetes in Patients with Nasopharyngeal Carcinoma Treated with Intensity-Modulated Radiation Therapy
    Hao Peng
    Lei Chen
    Yuan Zhang
    Wen-Fei Li
    Yan-Ping Mao
    Fan Zhang
    Rui Guo
    Li-Zhi Liu
    Ai-Hua Lin
    Ying Sun
    Jun Ma
    [J]. Scientific Reports, 6
  • [28] Prognostic value of hypothyroidism in patients undergoing intensity-modulated radiation therapy for nasopharyngeal carcinoma
    Weng, Jing-Jin
    Wei, Jia-Zhang
    Li, Min
    Ning, Le-Ping
    Liu, Fei
    Wei, Yun-Zhong
    Xiong, Wei-Ming
    Zhang, Ben-Jian
    Lu, Jin-Long
    Jiang, He
    Lu, Qiu-Tian
    Qu, Shen-Hong
    [J]. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2022, 44 (05): : 1114 - 1123
  • [29] Prognostic value of hypertension in patients with nasopharyngeal carcinoma treated with intensity-modulated radiation therapy
    Yin, Wen-Jing
    Chen, Dong-Ping
    Wang, Meng-Yao
    Zheng, Lu
    Dong, En-Lai
    Liu, Jin-Quan
    Qi, Bin
    [J]. ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (16)
  • [30] Outcomes and prognostic factors of conformal radiotherapy versus intensity-modulated radiotherapy for nasopharyngeal carcinoma
    Wei Lu Kuang
    Qin Zhou
    Liang Fang Shen
    [J]. Clinical and Translational Oncology, 2012, 14 : 783 - 790